GlobalData
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
Related Content
Media
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
Following the Bristol-Myers Squibb (BMS) announcement on 3 January 2019 that it will acquire Celgene in a cash and stock deal with an equity value of approximately $74 billion, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, offers her view on this significant merger
Media
Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019
In 2019, drug pricing pressure from regulators, patients, politicians and payers will remain and aggressive negotiation tactics to drive down drug prices are expected, says GlobalData, a leading data and analytics company
Media
R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData
Projected returns on investment in research and development (R&D) for the top 12 biopharmaceutical companies have fallen to 1.9%, according to a study by Deloitte’s Centre for Health Solutions leveraging revenue forecasts and industry benchmarks generated by GlobalData
Media
Drug development in neuroimmunology to witness strong growth in the 8MM
Drug development in neuroimmunology is expected to witness strong growth in the eight major markets (US, France, Germany, Italy, Spain, UK, Japan and China), primarily driven by deeper understanding of the underlying pathology of the various diseases, advancements in neurogenetics, and most importantly the potential of the field to develop drugs that offer targeted therapy mechanisms
Media
GSK and Pfizer deal shows shift in strategy shift to create the leader in over-the-counter products
Following today’s news that GlaxoSmithKline (GSK) and Pfizer have agreed to merge their respective consumer business units, in a deal valued at £9.8 billion, Maura Musciacco, Pharma Director at GlobalData, a leading data and analytics company, offers her view